UBS Upgrades Luminex to Buy | GenomeWeb

NEW YORK (GenomeWeb News) – UBS today upgraded Luminex to a Buy rating, noting uptake of the company's gastrointestinal panel, the Eragen acquisition, and a favorable profile amid macro challenges.

The investment bank upgraded the Austin, Texas-based company from a prior Neutral rating and lowered the 12-month price target on its stock to $22 from $25.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.